Patient-derived cancer organoids (PDCOs) are valuable for patient management and drug development. Label-free widefield optical redox ratio (WF-ORR) imaging measures organoid-level treatment response using the autofluorescence intensity of the metabolic co-enzymes NAD(P)H and FAD. We have developed WF-ORR imaging and analysis tools to maximize the accessibility, speed, sensitivity, and reproducibility of drug response measurements in PDCOs. These tools include leading-edge segmentation methods that isolate ORR changes within the proliferating zone of PDCOs, and single organoid tracking that reduces variability within drug screens. Overall, this approach enables rapid, sensitive, and reproducible measurements of treatment response and heterogeneity in PDCOs.
Access to the requested content is limited to institutions that have purchased or subscribe to SPIE eBooks.
You are receiving this notice because your organization may not have SPIE eBooks access.*
*Shibboleth/Open Athens users─please
sign in
to access your institution's subscriptions.
To obtain this item, you may purchase the complete book in print or electronic format on
SPIE.org.
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.